How to buy Capricor Therapeutics stock (CAPR)

Capricor Therapeutics is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.07 – a decrease of 1.43% over the previous week. Capricor Therapeutics employs 101 staff and has a trailing 12-month revenue of around $23.2 million.

Our top picks for where to buy Capricor Therapeutics stock

Buy Capricor Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Capricor Therapeutics stock price (NASDAQ: CAPR)

Use our graph to track the performance of CAPR stocks over time.

Capricor Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$13.07
52-week range	$3.52 - $23.40
50-day moving average more info button	$18.22
200-day moving average more info button	$8.89
Wall St. target price	$41.29
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.02

Is it a good time to buy Capricor Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Capricor Therapeutics price performance over time

Historical closes compared with the close of $12.9 from 2024-12-19

1 week (2024-12-13)	-2.71%
1 month (2024-11-21)	-27.49%
3 months (2024-09-20)	155.45%
6 months (2024-06-21)	174.47%

1 year (2023-12-21)	188.59%
2 years (2022-12-21)	253.42%
3 years (2021-12-21)	308.23%
5 years (2019-12-20)	1,128.57%

Capricor Therapeutics financials

Revenue TTM	$23.2 million
Gross profit TTM	$1.7 million
Return on assets TTM	-44.49%
Return on equity TTM	-392.69%
Profit margin	-146.86%
Book value	$0.73
Market Capitalization more info button	$569.3 million

TTM: trailing 12 months

Capricor Therapeutics share dividends

We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.

Have Capricor Therapeutics's shares ever split?

Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.

Capricor Therapeutics share price volatility

Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $3.52 up to $23.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 4.016. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Capricor Therapeutics overview

Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd.

Frequently asked questions

null
What percentage of Capricor Therapeutics is owned by insiders or institutions?
Currently 16.747% of Capricor Therapeutics shares are held by insiders and 18.534% by institutions. How many people work for Capricor Therapeutics?
Latest data suggests 101 work at Capricor Therapeutics. When does the fiscal year end for Capricor Therapeutics?
Capricor Therapeutics's fiscal year ends in December. Where is Capricor Therapeutics based?
Capricor Therapeutics's address is: 10865 Road to the Cure, San Diego, CA, United States, 92121 What is Capricor Therapeutics's ISIN number?
Capricor Therapeutics's international securities identification number is: US14070B3096 What is Capricor Therapeutics's CUSIP number?
Capricor Therapeutics's Committee on Uniform Securities Identification Procedures number is: 14070B309